Streetwise Biotech / Pharmaceuticals Articles



Biotech Delivers Positive Study Results for Prostate Cancer Prognostic Test
Source: Streetwise Reports  (12/5/18)
An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application. More >


Precision Medicine Developer Secures Another Patent for Drug Candidate
Source: Streetwise Reports  (12/5/18)
This company takes a step forward in its efforts to protect its intellectual property. More >


Biotech to Lead dMAB Tech Field with First Clinically Tested Product
Source: Streetwise Reports  (11/28/18)
An H.C. Wainwright & Co. report discussed recent articles covering results of this firm's preclinical studies. More >


Cannabis Provider to Debut Five More Dispensaries in Florida
Source: Streetwise Reports  (11/26/18)
This company plans to add even more this year as well. More >


Biopharma Agrees to $215 Million Acquisition Deal
Source: Streetwise Reports  (11/21/18)
An H.C. Wainwright & Co. report detailed the terms of the definitive agreement concerning the merger. More >


Biopharma to Accelerate Trial Timeline with Amendment
Source: Streetwise Reports  (11/21/18)
The change relates to the onset of dosing for patients with different degrees of disease. More >


Biotech Ramps Up Philippine Sales of Livestock Feed Premix
Source: Streetwise Reports  (11/21/18)
A distributor of the proprietary product places a third large order. More >


Life Science Company Addresses Antibiotic Resistance Problem
Source: Streetwise Reports  (11/18/18)
This firm's proprietary technology provides an alternative to antibiotic use in livestock production. More >


Biotech Files Patent Application for Nitric Oxide Delivery Device
Source: Streetwise Reports  (11/16/18)
With this development, the company advances blood/plasma transfusion technology.
More >


Daniel Carlson

Imprimis: Priming the Pumps for a Big 2019
Source: Daniel Carlson for Streetwise Reports  (11/15/18)
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on. More >


Catalysts Approaching for U.S. Developer of Cancer Therapeutics
Source: Streetwise Reports  (11/10/18)
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch. More >


Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting
Source: Streetwise Reports  (11/10/18)
A ROTH Capital Partners report relayed the contents of both presented abstracts. More >


Target Price Raised on Biotech in Anticipation of Clinical Trial Presentation
Source: Streetwise Reports  (11/7/18)
An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy. More >


Coverage Initiated on Developer of Targeted Gene Therapies for Cancer
Source: Streetwise Reports  (11/7/18)
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. More >


Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says
Source: Streetwise Reports  (11/7/18)
This firm explains how its 15 years in drug development led to and supports this conclusion. More >


Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'
Source: Streetwise Reports  (10/31/18)
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. More >


Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment
Source: Streetwise Reports  (10/31/18)
With this achievement, the firm expands its potential partnering opportunities. More >


Daniel Carlson

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. More >


Daniel Carlson

Catasys…Future's So Bright
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. More >


Biotech to Expand Precision Medicine Services via New Partnership
Source: Streetwise Reports  (10/24/18)
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. More >


Frederick Lacy

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View
Source: Fincom Investment Partners for Streetwise Reports  (10/24/18)
Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp. More >


Biotech Advances Monoclonal Antibody Technology and Is Awarded Gates Foundation Grant
Source: Streetwise Reports  (10/20/18)
An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology. More >


Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner
Source: Streetwise Reports  (10/17/18)
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space. More >


Biotech Reports Encouraging Interim Gene Therapy Data for Skin Disorder
Source: Streetwise Reports  (10/17/18)
This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication. More >


Tech Firm Launches Medical Cannabis User Data App, Lands Partnership
Source: Streetwise Reports  (10/13/18)
This "patient-care solution" is designed to help retailers make product recommendations. More >


Showing Results: 1 to 25 of 817 Next

Notable Quotes

"SSC's U.K. subsidiary received a technology order for 16 restaurants."
– Ron Struthers, Struthers Resource Stock Report
"I've found a standout in PLL."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"PMN is looking to outlicense PMN310 after the Phase 1 study."
– André Uddin, Mackie Research Capital

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe